Panaxia Pharmaceutical Industries Ltd., or Panaxia Global, is a global company headquartered in Lod, Israel, that develops, manufactures and markets medical cannabis-based products in pharmaceutical quality. The company has commercial activity in Germany, France, Cyprus and Malta. Panaxia is the controlling shareholder of Panaxia Labs Israel Ltd., which is traded on the Tel-Aviv Stock Exchange. Panaxia USA (a subsidiary of Panaxia Global) manufactures medical cannabis-based products in North America.
History
In 2010, Panaxia was founded as the cannabis division of the Segal Pharma Group, a group of private companies in the pharmaceutical and medical device spaces. Upon its establishment, the company began research and development in the field of medical cannabis.
In 2016, upon the government's announcement of the outline for medicalization of medical cannabis products,[2] Panaxia Pharmaceutical Industries Ltd. was founded by Dr. Dadi Segal, Dr. Eran Goldberg and Adv. Assi Rotbart as a separate company controlled by the Segal Group.
In 2018, Panaxia began cooperating with Rafa Laboratories, which was the first pharmaceutical company in Israel to enter the medical cannabis arena. As part of this partnership, Panaxia manufacturers cannabis oils for Rafa under the Axiban brand. In 2018, Panaxia began distributing medical cannabis products to various pharmacies in Israel.